[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1588
1. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS: Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol; 2007 Jun;127(6):1351-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma.
  • Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).
  • The main outcome was tumor-related quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Basal Cell / surgery. Quality of Life. Skin Neoplasms / psychology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / surgery. Emotions. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Middle Aged. Mohs Surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301830.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR 02203-01
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


2. Vasconcelos HM Jr, Almeida AL, Sagawa A, Carvalho RM, Avila MP: [An advanced case of basosquamous carcinoma of the orbit: case report]. Arq Bras Oftalmol; 2009 Nov-Dec;72(6):819-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of basosquamous carcinoma of the orbit: case report].
  • [Transliterated title] Carcinoma basoescamoso avançado de órbita: relato de caso.
  • Basosquamous carcinoma is a rare tumor with features of both basal cell and squamous cell carcinoma, linked by a transition area.
  • It is a rare epithelial neoplasm with a tendency for local recurrence.
  • It also has a high incidence of distant metastasis, a condition that differentiates it from the basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Orbital Neoplasms / pathology. Patient Compliance
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098906.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Kang SY, Lee KG, Lee W, Shim JY, Ji SI, Chung KW, Chung YK, Kim NK: Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci; 2007 May;98(5):716-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population.
  • Unrepaired damage can result in apoptosis or may lead to unregulated cell growth and cancer.
  • This hospital-based case-control study examined whether polymorphisms in the DNA repair gene X-ray repair cross-complementing groups 1 (XRCC1) (Arg194Trp[C > T], Arg280His[G > A] and Arg399Gln[G > A]) play a role in susceptibility to skin cancer.
  • We genotyped these polymorphisms for 212 histopathologically confirmed skin cancer cases (n = 114 basal cell carcinoma, n = 98 squamous cell carcinoma) and 207 age- and sex-matched healthy control cases in Korea.
  • We found that individuals with the Arg/Gln and Arg/Gln + Gln/Gln genotypes at XRCC1 Arg399Gln(G > A) had an approximately 2-fold increased risk of basal cell carcinoma compared to individuals with the Arg/Arg genotype (adjusted odds ratio [AOR] = 2.812, 95% confidence interval [CI] 1.32-5.98, and AOR = 2.324, 95% CI 1.11-4.86).
  • However, we observed that the 194Trp allele of the Arg194Trp(C > T) polymorphism was inversely associated with squamous cell carcinoma risk (Trp/Trp, AOR = 0.06, 95% CI 0.006-0.63).
  • Our data suggest that the Arg194Trp and Arg399Gln polymorphisms may be differentially associated with skin cancer risk.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group / genetics. Case-Control Studies. Gene Frequency. Genetic Predisposition to Disease / ethnology. Genotype. Haplotypes. Humans. Korea. Middle Aged. Odds Ratio

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355263.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
  •  go-up   go-down


Advertisement
4. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M: Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol; 2008 Feb;21(2):178-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
  • Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.
  • In addition, a comparison with squamous cell carcinoma has not been reported previously.
  • In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation.
  • We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative.
  • Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories.
  • While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases.
  • Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10.
  • BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma.
  • In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation.
  • Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Skin Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods. Skin Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065959.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-15; 0 / human epithelial antigen-125
  •  go-up   go-down


5. Eide MJ, Weinstock MA, Dufresne RG Jr, Neelagaru S, Risica P, Burkholder GJ, Upegui D, Phillips KA, Armstrong BK, Robinson-Bostom L: Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin). J Invest Dermatol; 2005 Feb;124(2):308-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).
  • Larger keratinocyte carcinoma (KC) lesions are associated with higher morbidity.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 May;37(7):843-8 [11313171.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):476-83 [11260002.001]
  • [Cites] Dermatol Surg. 2001 Nov;27(11):955-9 [11737130.001]
  • [Cites] Br J Dermatol. 2002 Jul;147(1):48-54 [12100184.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1043-51 [12164742.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):389-94 [12170189.001]
  • [Cites] Ann Plast Surg. 2002 Oct;49(4):439-42 [12370654.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Psychiatry. 1967 Jan;113(494):89-93 [6029373.001]
  • [Cites] J Dermatol Surg Oncol. 1981 Apr;7(4):311-6 [7240532.001]
  • [Cites] Prog Clin Biol Res. 1984;156:169-79 [6473424.001]
  • [Cites] J Psychosom Res. 1985;29(2):139-53 [4009515.001]
  • [Cites] J Am Acad Dermatol. 1988 Mar;18(3):591-8 [3351022.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] Eur J Surg Oncol. 1989 Apr;15(2):143-8 [2703058.001]
  • [Cites] Arch Dermatol. 1991 Mar;127(3):356-61 [1998366.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Postgrad Med. 1991 Mar;89(4):151-2, 155-8 [2000349.001]
  • [Cites] Ann R Coll Surg Engl. 1991 Jul;73(4):248-52 [1863047.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):713-8 [1890243.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2064-8 [1913555.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):255-61 [8599737.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9 [9308558.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):269-74 [10086447.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):339-40 [10086457.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1111-6 [10527006.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):783-7 [10583157.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):876-9 [10583170.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):271-9 [10861504.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):280-5 [10861505.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • (PMID = 15675948.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS12744; NLM/ PMC1613794
  •  go-up   go-down


6. Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, Bavinck JN, Perry AE, Spencer SK, Daling J, Green AC, Pawlita M, New Hampshire Skin Cancer Study Group: Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ; 2010 Jul 08;341:c2986
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study.
  • OBJECTIVE: To investigate the association between genus beta human papillomaviruses and the incidence of non-melanocytic skin cancer in the general population.
  • PARTICIPANTS: 2366 skin cancer cases and controls from the general population aged 25 to 74 years (663 squamous cell carcinoma, 898 basal cell carcinoma, 805 controls), with plasma samples tested for L1 antibodies to 16 genus beta human papillomaviruses by multiplex serology.
  • MAIN OUTCOME MEASURES: Odds ratios for squamous cell carcinoma and basal cell carcinoma associated with seropositivity to beta human papillomaviruses.
  • RESULTS: Squamous cell carcinoma, but not basal cell carcinoma, cases had a higher prevalence of each of the individual beta human papillomaviruses assayed compared with controls.
  • The odds ratios for squamous cell carcinoma increased with the number of beta types positive (odds ratio for one type positive 0.99 (95% confidence interval 0.74 to 1.33); two to three types positive 1.44 (1.03 to 2.01); four to eight types positive 1.51 (1.03 to 2.20); more than eight types positive 1.71 (1.12 to 2.62); P for trend (categorical)<0.001; P for trend (continuous)=0.003).
  • CONCLUSIONS: These findings support a relation between genus beta human papillomavirus infection and the incidence of squamous cell carcinoma of the skin in the general population, as well as potential enhancement of risk by immunosuppression.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Jan;142(1):103-9 [10651702.001]
  • [Cites] J Virol. 2008 Nov;82(21):10408-17 [18715924.001]
  • [Cites] J Immunol Methods. 2001 Jul 1;253(1-2):153-62 [11384677.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):683-6 [11531252.001]
  • [Cites] J Virol Methods. 2002 Oct;106(1):61-70 [12367730.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):709-11 [15126608.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Am J Epidemiol. 1976 Feb;103(2):226-35 [1251836.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] J Virol. 1990 Sep;64(9):4399-406 [2166821.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):789-95 [2202901.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):650-62 [2071226.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):367-92 [8080949.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):696-701 [9764856.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1845-53 [16099939.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):529-35 [16537712.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):719-26 [17204514.001]
  • [Cites] Dis Markers. 2007;23(4):247-59 [17627060.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1862-8 [17565742.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):189-95 [18199724.001]
  • [Cites] PLoS Pathog. 2008 Jun;4(6):e1000091 [18566657.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1731-8 [18628425.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):457-9 [18503604.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • (PMID = 20616098.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA57494; United States / NCI NIH HHS / CA / R01 CA118443; United States / NCI NIH HHS / CA / CA118443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral
  • [Other-IDs] NLM/ PMC2900549
  • [Investigator] Anderson DR; Averill RW; Aversa AJ; Brady S; Bairstow BA; Baughman RD; Blasik LG; Campbell J; Carroll C; Chapman MS; Clendenning WE; Collison DW; Crespo JL; Danby FW; Del Guidice SM; Dimond RL; Dinulos JG; Draper WS; Finkle JP; Fisher J; Fournier J; Frank WE; Fromer JL; Goldberg NC; Goldminz D; Gordon R; Greenstein DS; Habif TP; Hammer C; Hokanson T; Joselow SA; Lewis G; Lichter MD; Liranzo MO; Margesson L; Mittleman MA; Peraza J; Posnick RB; Pringle WM; Quitadamo M; Reohr PB; Reynolds NC; Ryan A; Sands P; Schwartz ME; Seymour G; Sherman LD; Sisto JA; Spencer SK; Starke JC; Stewart MI; Sullivan S; Thyresson NH; Truhan AP; Tye MJ; Watson J; Waterson KW; Willer R; Zug K
  •  go-up   go-down


7. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1074-176
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.
  • BACKGROUND: Superficial skin biopsies of basal cell carcinoma (BCC) represent some of the most common dermatopathology specimens.
  • Superficial shave biopsies containing partial samples of lesions with squamatization present difficulties in distinguishing BCC from squamous cell carcinoma (SCC).
  • METHODS: We collected 12 cases of superficial biopsies of BCC with centrally located cords and strands suggesting squamous differentiation at the Yale Dermatopathology Laboratory over a 3-month period and stained them with BerEP4.
  • CONCLUSIONS: BerEP4 labeling is not reliable in superficial biopsies of BCC with squamoid features.
  • It is important to be aware of this caveat in interpreting BerEP4 staining for BCC and SCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19187107.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


8. Rong Y, Welsh JS: Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta). Med Phys; 2010 Oct;37(10):5509-5517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta).
  • PURPOSE: The Xoft Axxent<sup>®</sup> x-ray source has been used for treating nonmelanoma skin cancer since the surface applicators became clinically available in 2009.
  • The TG-61 in-air method was used as a guideline for acquiring nominal dose-rate output at the skin surface.
  • GafChromic<sup>®</sup> EBT films were used for testing the properties of the treatment fields with the skin applicators.
  • Patients with basal cell or squamous cell carcinoma were treated with eBx using a calibrated Xoft system with the low-energy x-ray source and the skin applicators.
  • RESULTS: The average nominal dose-rate output at the skin surface for the 35 mm applicator is 1.35 Gy/min with ±5% variation for 16 sources.
  • CONCLUSIONS: Together with TG-61, the authors' methodology provides comprehensive calibration procedures for medical physicists for using the Xoft eBx system and skin applicators for nonmelanoma skin cancer treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524537.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Calibration / Cancer / Dosimetry / Dosimetry/exposure assessment / Ionization chambers / Lead / Radiation treatment / Skin / Standards and calibration / Surface treatments / Therapeutic applications, including brachytherapy / X-rays / basal cell carcinoma / biomedical equipment / brachytherapy / calibration / cancer / dosimetry / electronic brachytherapy / nonmelanoma skin cancer / skin / squamous cell carcinoma / surface applicator
  •  go-up   go-down


9. Chan S, Dhadda AS, Swindell R: Single fraction radiotherapy for small superficial carcinoma of the skin. Clin Oncol (R Coll Radiol); 2007 May;19(4):256-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single fraction radiotherapy for small superficial carcinoma of the skin.
  • AIMS: To define the optimal dose and maximum tumour size of basal and squamous cell carcinoma of skin that can be treated by single fraction radiotherapy.
  • MATERIALS AND METHODS: A review was undertaken of 1005 lesions of basal/squamous cell carcinoma of the skin involving 806 patients treated at a single centre with 10 years of follow-up.
  • RESULTS: The overall disease-free and necrosis-free rates at 5 years were 90% and 84%, respectively.
  • The crude 10-year recurrence rate was 4% (95% CI 3.4-5.4%), with late skin necrosis at 6% (95% CI 4.8-7.2%).
  • There was no difference in tumour recurrence rates between 20 and 22.5 Gy (P=0.3), but there was a significantly higher skin necrosis rate at the treated site in the patients who had received 22.5 Gy (P=0.003).
  • Most skin necrosis healed spontaneously, with only 16% requiring surgical intervention.
  • CONCLUSIONS: Single fraction radiotherapy is an acceptable treatment for small superficial BCC and SCC of the head and neck region in patients who have difficulty attending multiple hospital visits as long as the field size required for treatment is no larger than 3 cm in diameter.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Disease-Free Survival. England / epidemiology. Female. Humans. Male. Medical Records. Middle Aged. Necrosis / pathology. Radiation Dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379488.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Lim P, Paver R, Peñas PF: Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). J Am Acad Dermatol; 2010 Nov;63(5):832-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007).
  • OBJECTIVE: We sought to evaluate changes over time in the type of patients and skin cancers that are treated using MMS, and the repairs used to close the defects.
  • METHODS: We conducted a retrospective study on patients treated with MMS at the Skin and Cancer Foundation Australia, Westmead, in 1997 against those treated in 2007.
  • Patient demographics (age, sex), pathology of tumor, anatomic site of the tumor, preoperative tumor size, postoperative defect size, and repair method were analyzed.
  • The 2007 cohort was a little older (62 vs 64 years), but there were no differences in sex, anatomic site, rate of basal/squamous cell carcinoma, squamous cell carcinoma histologic subtypes, or preoperative tumor size.
  • However, there were fewer superficial basal cell carcinomas, and the postoperative defect size was smaller in 2007 (P < .0001).
  • CONCLUSION: Although tumor size and the percentage of tumors in each anatomic site did not change over 10 years, the size of the defect created after MMS has become smaller.
  • This reduction in defect size may explain why more defects are now repaired by side-to-side closure and flap repairs whereas fewer defects are repaired by skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Mohs Surgery / statistics & numerical data. Mohs Surgery / utilization. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin Transplantation / statistics & numerical data. Skin Transplantation / utilization. Surgical Flaps / statistics & numerical data. Surgical Flaps / utilization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20950738.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


13. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • RESULTS: The behavior of this tumor is very aggressive, resulting in poor prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


15. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • [Transliterated title] Aktuelle Therapieempfehlungen für das Basalzellkarzinom und Plattenepithelkarzinom der Haut.
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


16. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):338-9 [10457144.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):424-31 [2925988.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2004 Sep;30(9):1214-8 [15355363.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:43-9 [14616349.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20 [15056141.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] Dermatol Surg. 2001 Feb;27(2):143-6 [11207687.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):720-6 [1820764.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


17. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • Prior to ALA-PDT 74 NMSC's were documented: 40 (54%) BCC and 34 (46%) SCC.
  • 46 NMSC's were documented following ALA-PDT: 22 (48%) BCC and 24 (52%) SCC.
  • Prior to ALA-PDT, the frequency of BCC averaged 2 [IQR 1 to 3, max=4], and the frequency of SCC averaged 1 [IQR 1 to 1, max=3].
  • Following ALA-PDT, the occurrence of BCC averaged 1 [IQR 0 to 1, max=5], and that of SCC averaged 1 [IQR 0 to 2, max= 4].
  • The difference between BCC frequency before and after ALA-PDT treatment shown a significant reduction in BCC incidence (P = 0.0018).
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous or tubular carcinoma was frequently seen in the Luminal A type.
  • Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type.
  • Pathological response rate of NAC, including grade 2 and 3, was higher in TN tumor as 51.5 % (22/53) than in Luminal A tumor as 16.7% (12/72).
  • Central reviews of immunohistochemistry, such as ER, PgR, HER2, CK5/6, EGFR etc, will be confirmed in this cohort, for TN tumors are similar to basal-like tumors discriminated by gene- profiling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis; 2006 Aug;27(8):1670-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPA, haplotypes, and risk of basal and squamous cell carcinoma.
  • Nucleotide excision repair (NER) is instrumental in removing DNA lesions caused by ultraviolet (UV) radiation, the dominant risk factor for keratinocyte carcinoma, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • We evaluated whether BCC or SCC risk was influenced by the A23G single nucleotide polymorphism (SNP) in Xeroderma pigmentosum group A (XPA), which codes for an essential protein in NER.
  • We also investigated whether haplotypes of XPA, determined by seven haplotype-tagging SNPs, better define susceptibility to keratinocyte carcinoma.
  • Incident cases of BCC and SCC from New Hampshire were identified through dermatologists and pathology laboratories.
  • Cases of BCC (886) and of SCC (682) were compared with controls (796).
  • Using GG as the reference, the A allele was less frequent among cases of BCC (OR(AG) = 0.82, 95% CI (0.66, 1.01); OR(AA)= 0.74, 95% CI (0.53, 1.03); trend test P = 0.03) and SCC (OR(AG) = 0.85, 95% CI (0.67, 1.07); OR(AA) = 0.74, 95% CI (0.52, 1.05); trend test P = 0.05) than controls.
  • Risk from > or =3 severe sunburns was elevated for those with the GG genotype only, and this interaction was nearly significant for BCC (P = 0.07).
  • Using a haplotype analysis identifying seven common XPA haplotypes indicated that the A23G polymorphism alone captured the differences in susceptibility to keratinocyte carcinoma.
  • The common G allele of the A23G polymorphism was associated with an increased risk of BCC and SCC and this polymorphism appeared to be the determining polymorphism in XPA that alters cancer susceptibility.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Haplotypes / genetics. Skin Neoplasms / genetics. Xeroderma Pigmentosum Group A Protein / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513681.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006515; United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein
  •  go-up   go-down


21. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


22. Costantino D, Lowe L, Brown DL: Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg; 2006;59(4):424-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature.
  • Basosquamous carcinoma of the skin is a relatively rare cutaneous neoplasm that has been shown to have significant metastatic potential.
  • Histopathologists debate whether these lesions arise de novo or differentiate from pre-existing basal cell carcinomas.
  • We present a case in which a longstanding lesion initially diagnosed as basal cell carcinoma was later found to have basosquamous histology and regional metastases.
  • Review of the literature reveals a metastatic rate greater than that of basal cell and squamous cell carcinoma, and identifies several important characteristics that impact prognosis after surgical resection.
  • For physicians treating carcinomas of the skin, it is important to understand the natural history and proper treatment of this aggressive neoplasm.
  • [MeSH-major] Carcinoma, Basosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Foot Diseases / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756261.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


23. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P: Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol; 2008 Nov;33(6):745-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans.
  • We describe a new treatment for BCC and SCC.
  • METHODS: In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment.
  • CONCLUSION: The results indicated that brachytherapy is an effective treatment for BCC and SCC.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681873.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ointments; 7440-15-5 / Rhenium
  •  go-up   go-down


24. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects and a 6-month follow-up or posttreatment histologic evaluation.
  • DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.
  • Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.
  • Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ.
  • CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026854.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 47
  •  go-up   go-down


25. Ball EA, Hussain M, Moss AL: Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol; 2005 May;30(3):259-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.
  • The development of a basal cell carcinoma within a naevus sebaceous of Jadassohn (NSJ) has commonly been reported.
  • However, the development of a squamous cell carcinoma (SCC) is rare.
  • Of these only one was a case of simultaneous occurrence of squamous and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Multiple Primary / etiology. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Male. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807685.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


26. Skaria AM: Recurrence of basosquamous carcinoma after Mohs micrographic surgery. Dermatology; 2010;221(4):352-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of basosquamous carcinoma after Mohs micrographic surgery.
  • BACKGROUND: The recurrence rate of basal cell carcinoma (BCC) after Mohs micrographic surgery (MMS) is well documented.
  • SUBJECTS AND METHODS: We investigated 1,000 cases of epidermal tumors in a private center of MMS including BCC, squamous cell carcinoma and basosquamous carcinoma (BSC) treated by MMS from 1998 to 2007 in a retrospective study.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Mohs Surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Female. Humans. Incidence. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20924160.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The authors confine the use of the term to an infiltrative growth BCC with areas of keratinization and/or intercellular bridge formation in the setting of a prototypic proliferative stromal reaction.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103364.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


28. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Feb;30(2):340-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.
  • Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.
  • We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.
  • Here, we investigated the protective role of endogenous estrogen in skin keratinocyte tumorigenesis.
  • Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for BCC induction or topically treated with chemical carcinogens for SCC induction.
  • Susceptibility to BCC or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.
  • Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.
  • We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
  • Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma skin carcinogenesis, with a key role played by cyclin D1.
  • Our findings underscore a highly protective role of endogenous estrogen against skin tumorigenesis by diverse agents in two independent mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays


29. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation, while in areas of squamous differentiation was negative.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differentiated suprabasal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


30. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Skin cancer provides an advantageous model for studying the development of cancer.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • A high frequency of epidermal p53 clones has been detected in chronically sun-exposed skin.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Microdissection-based studies have also shown that different parts of individual BCC tumors can share a common p53 mutation yet differ with respect to additional alterations within the p53 gene, consistent with subclonal development within tumors.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748639.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 79
  •  go-up   go-down


31. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Sebaceous carcinoma (SEB) is the most important malignant tumor of the eyelid.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • In this study, the expression of androgen receptor (AR) in SEB, SCC, and BCC was evaluated.
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


33. Sharquie KE, Al-Meshhadani SA, Al-Nuaimy AA: Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis. Saudi Med J; 2007 May;28(5):787-90
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the eyes in patients with epidermodysplasia verruciformis.
  • They developed frequent multiple basal and squamous cell carcinoma, all of them had periorbital squamous cell carcinoma that invaded the orbit and ended with enucleation of their eyes.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Epidermodysplasia Verruciformis / complications. Orbital Neoplasms / complications
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / complications. Eye Enucleation. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457453.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


34. Perrem K, Lynch A, Al Nooh F, Leader M, Elaine Kay: The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol; 2008 Jul;39(7):1034-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population.
  • Renal transplant recipients incur markedly higher rates of nonmelanoma skin cancer, including both basal and squamous cell carcinoma, by unknown mechanisms that are thought to be activated by long-term immunosuppression.
  • These tumors typically arise in sun-exposed areas of the skin and are biologically more aggressive in renal transplant recipients compared with nontransplant patients.
  • Interestingly also, the incidence of squamous cell carcinoma is generally 2- to 3-fold higher than that of basal cell carcinoma in renal transplant recipients, which is a reversal of the trend in the nontransplant population.
  • We have shown in a previous report that the increased incidence of squamous cell carcinoma in renal transplant patients is characterized by increased telomere lengths when compared with the same tumors in the nontransplant population.
  • In our current study, we performed a similar analysis of a cohort of 35 basal cell carcinoma samples from both the renal transplant and nontransplant patient groups.
  • We find that, in contrast to the situation in squamous cell carcinoma, the telomeres of the basal cell carcinomas in renal transplant recipients are in fact shorter than their counterparts in the nontransplant population, but also that these lengths are considerably longer in both cases than their squamous cell counterparts.
  • This is the first report to comprehensively show that the telomere lengths significantly differ between basal and squamous cell carcinomas.
  • These data also suggest that future treatment strategies for nonmelanoma skin cancers that are based upon telomerase inhibition, including those arising in transplant patients, may require different approaches for these two different skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Kidney Transplantation. Skin Neoplasms / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482746.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Russo GG: Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin Dermatol; 2005 Nov-Dec;23(6):581-6
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments.
  • This contribution will discuss the treatment of actinic keratoses, basal cell carcinomas, and squamous cell carcinoma using methods that are not routinely established but have been used for a long period.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Keratosis / drug therapy. Photosensitivity Disorders / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325066.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid; SML2Y3J35T / Colchicine
  • [Number-of-references] 53
  •  go-up   go-down


36. Flanagan AM, Rafferty G, O'Neill A, Rynne L, Kelly J, McCann J, Carty MP: The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin. Int J Mol Med; 2007 Apr;19(4):589-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin.
  • Skin cancer, the most common cancer in the general population, is strongly associated with exposure to the ultraviolet component of sunlight.
  • To investigate the relationship between DNA damage processing and skin tumour development, we determined the POLH status of a cohort of skin cancer patients.
  • In the absence of active poleta in xeroderma pigmentosum variant (XPV) patients, mutations accumulate at sites of UV-induced DNA damage, providing the initiating step in skin carcinogenesis.
  • Forty patients diagnosed with skin cancer were genotyped for polymorphisms in the POLH protein-coding sequence, using glycosylase-mediated polymorphism detection (GMPD) and direct DNA sequencing of POLH PCR products derived from white blood cell genomic DNA.
  • No POLH mutations were identified in genomic DNA from skin tumours derived from 15 of these patients.
  • As determined by RT-PCR, POLH mRNA was expressed in all normal and skin tumour tissue examined.
  • Poleta protein was also detectable by Western blotting, in two matched normal and skin tumour extracts.
  • An alternatively spliced form of POLH mRNA, lacking exon 2, was more readily detected in skin tissue than in white blood cells from the same patient.
  • Real-time PCR was used to quantify POLH expression in matched normal and skin tumour-derived mRNA from a series of patients diagnosed with either basal or squamous cell carcinoma.
  • Compared to matched normal skin tissue from the same patient, 1 of 7 SCC, and 4 of 10 BCC tumours examined showed at least a 2-fold reduction in POLH expression, while 1 of 7 SCC, and 3 of 10 BCC tumours showed at least a 2-fold increase in POLH expression.
  • Differences in gene expression, rather than sequence changes may be the main mechanism by which POLH status varies between normal and skin tumours in the population under investigation.
  • Knowledge of the POLH status in skin tumours could contribute to an understanding of the role of this gene in the development of the most common cancer in the general population.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA-Directed DNA Polymerase / genetics. Gene Expression. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334634.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein
  •  go-up   go-down


37. Askari SK, Schram SE, Wenner RA, Bowers S, Liu A, Bangerter AK, Warshaw EM: Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. J Am Acad Dermatol; 2007 May;56(5):739-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population.
  • BACKGROUND: Presenting signs/symptoms of skin cancer may aid in earlier detection and diagnosis.
  • OBJECTIVE: We sought to compare prospectively collected, presenting signs/symptoms of malignant melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and seborrheic keratosis (SK).
  • METHODS: This analysis was part of a larger study on teledermatology involving 3039 skin neoplasms in 2152 patients at a Department of Veterans Affairs medical center.
  • At presentation, participants were asked about signs/symptoms of specific skin lesions.
  • In all, 912 biopsy-proven MM (39), BCC (411), SCC (238), and SK (224) were included in this analysis.
  • RESULTS: "No symptoms" was reported more often with MM (82%) as compared with BCC (relative risk [RR] 2.26, confidence interval [CI] 1.86, 2.75), SCC (RR 3.31, CI 2.54, 4.32), or SK (RR 2.0, CI 1.61, 2.48; all P < .0001).
  • Tenderness was more commonly reported with SCC (40%) as compared with MM (RR 15.9, CI 2.28, 110.69), SK (RR 3.0, CI 2.11, 4.39), or BCC (RR 2.6, CI 1.97, 3.38; all P < .0001).
  • Bleeding was more commonly reported with BCC (37%) as compared with SK (RR 2.3, CI 1.67, 3.20), SCC (RR 1.6, CI 1.22, 2.05), or MM (RR 29.8, CI 1.89, 469.65; all P <or= .007).
  • CONCLUSION: This study describes common signs/symptoms of BCC, SCC, and SK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratosis, Seborrheic / diagnosis. Melanoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prospective Studies. Skin Neoplasms / diagnosis


38. Qureshi AA, Laden F, Colditz GA, Hunter DJ: Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med; 2008 Mar 10;168(5):501-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma.
  • BACKGROUND: Occurrences of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) have been associated with varying geography.
  • Our goal was to evaluate differences in risk of these skin cancers according to residence at varying UV indices at 3 time points.
  • The outcome measure was diagnosis of melanoma, SCC, or BCC.
  • RESULTS: During the 18-year study, 420 cases of melanoma, 863 cases of SCC, and 8215 cases of BCC occurred.
  • Although elevated, the age-adjusted risk of BCC at 30 years of age associated with residence in these states was substantially less.
  • CONCLUSIONS: The risk of SCC is independently affected by residence in locations with medium and high UV indices; the gradient of risk is weaker for BCC; and the risk of melanoma does not change significantly across this gradient.


39. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • Further analysis with existing facial BCC and SK density data did not however show a direct relationship with the measured UV exposures highlighting the importance of other factors influencing the causation and localisation of facial NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H: Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology; 2008;217(3):215-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans.
  • Occasionally, B-cell lymphoma may develop in these patients, and additional neoplastic complications such as basal cell carcinoma or squamous cell carcinoma (SCC) have been reported once each over the past 60 years.
  • [MeSH-major] Acrodermatitis / complications. Borrelia burgdorferi. Carcinoma, Squamous Cell / etiology. Lyme Disease / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Ankle. Chronic Disease. Female. Humans. Neoplasm Metastasis


41. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA; 2005 Aug 10;294(6):681-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
  • CONTEXT: The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years.
  • OBJECTIVES: To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample.
  • PARTICIPANTS: Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003.
  • MAIN OUTCOME MEASURES: Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time.
  • RESULTS: During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients.
  • Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous cell carcinomas.
  • Overall, the age-adjusted incidence of basal cell carcinoma per 100,000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% CI, 17.8-23.9) for men.
  • The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P = .19).
  • Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype.
  • The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100 000 persons of 3.9 (95% CI, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P = .01) and men (P = .04).
  • CONCLUSIONS: This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota.
  • There was a disproportionate increase in basal cell carcinoma in young women.
  • This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418458.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):279; author reply 279-81 [16418459.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278-9; author reply 279-81 [16418456.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418457.001]
  • (PMID = 16091570.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kang SY, Lee SJ, Hong SH, Chung YK, Oh HS, Kim SW, Yim DJ, Kim NK: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin. Mol Med Rep; 2010 Sep-Oct;3(5):741-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
  • Genetic instability resulting from mutations in repair genes, defects in folic acid metabolism or DNA synthesis has been reported to contribute significantly to the development of skin cancer.
  • Thus, the present case-control study was conducted to determine whether an association exists between the MTHFR/TS polymorphisms and squamous cell carcinoma (SCC) and/or basal cell carcinoma (BCC) among Korean individuals.
  • The study subjects comprised 95 patients with SCC, 100 patients with BCC and 207 controls with no evidence of malignancy or pre-malignant lesions.
  • Patients with skin cancer and control samples were analyzed for polymorphisms of the MTHFR or TS genes by means of polymerase chain reaction-restriction fragment length polymorphism.
  • The MTHFR 677C>T and MTHFR 1298A>C polymorphisms showed no significance with regard to the development of SCC and BCC.
  • However, within the 6 bp insertion (ins)/deletion (del) polymorphism in the 3'-untranslated region (3'-UTR) of the TS gene, the BCC group showed statistical significance with a 2.8-fold increased risk of cancer development [adjusted odds ratio (AOR)=2.821] in heterozygous mutations (0 bp/6 bp), 7.5-fold (AOR=7.539) in homozygous mutations (6 bp/6 bp) and 3-fold (AOR=3.079) upon combination of heterozygous mutations and homozygous mutations (0 bp/6 bp + 6 bp/6 bp).
  • We thus conclude that the 6 bp ins/del polymorphism in the 3'-UTR is associated with increased risk of the development of skin cancer among Korean individuals with BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472308.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


43. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM: Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol; 2007 Nov;143(11):1386-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
  • OBJECTIVE: To identify predictors of skin-related quality of life (QOL) after treatment of nonmelanoma skin cancer (NMSC).
  • SETTING: University-affiliated private practice and a Veterans Affairs clinic.
  • MAIN OUTCOME MEASURE: Skin-related QOL, measured with the 16-item version of Skindex-16, a validated measure.
  • RESULTS: Controlling for treatment group, the strongest independent predictor of skin-related QOL after treatment of NMSC was pretreatment skin-related QOL.
  • No tumor or care characteristic (including location of tumor, size of tumor, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better skin-related QOL after treatment of NMSC.
  • CONCLUSIONS: Patients with better pretreatment skin-related QOL, less comorbidity, and better mental health status had better skin-related QOL after treatment of NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Quality of Life. Skin / physiopathology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2007 Nov;143(11):1429-32 [18025368.001]
  • [ErratumIn] Arch Dermatol. 2008 Feb;144(2):230
  • (PMID = 18025362.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


44. Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS: Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol; 2010 Sep;63(3):400-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel cell carcinoma (MCC) tumors.
  • Polymerase chain reaction-based detection of the virus in other nonmelanoma skin cancers, however, has been inconsistent and controversial.
  • OBJECTIVE: We sought to directly assay for MCV infection in squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) tumor cells by immunostaining for viral antigen.
  • METHODS: CM2B4, a monoclonal antibody to exon 2 peptides of MCV T antigen, was used to examine tumors from 20 patients with MCC with and without secondary SCC or BCC tumors.
  • RESULTS: MCV T antigen was readily detected in 15 (75%) of 20 MCC tumors including 11 MCC tumors from patients with secondary SCC or BCC.
  • In contrast to MCC, none of these secondary BCC or SCC was MCV T-antigen positive.
  • CONCLUSIONS: MCV T antigen is generally not expressed in BCC or SCC tumors from a population favored to have MCV infection, ie, those persons already given the diagnosis of MCV-positive MCC.
  • This suggests that episodic polymerase chain reaction detection of MCV genome in BCC or SCC tumors may represent coincidental rather than causal infection, and that these tumors share other noninfectious risk factors.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / virology. Immunocompetence. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20584559.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA120726; United States / NCI NIH HHS / CA / CA136363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


45. Dhouib H, Mnejja M, Ayadi L, Hammami B, Boudawara T, Ghorbel A: [Cutaneous basosquamous carcinoma]. Ann Otolaryngol Chir Cervicofac; 2009 Mar;126(1):25-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous basosquamous carcinoma].
  • [Transliterated title] Carcinome basocellulaire métatypique.
  • INTRODUCTION: Basosquamous carcinoma is a rare entity that essentially affects the head and neck region in male patients.
  • The authors present the clinical signs and progression as well as the therapeutic consequences of this disease through two observations.
  • CASE REPORT 1: A 41-year-old man presented with basosquamous carcinoma of the right temporoparietal region treated initially with surgery alone.
  • Five years later, he was operated on for a local and lymph node recurrence followed by radiation therapy, stabilizing the disease for 4 years; subsequently a second recurrence with metastasis to the chest area occurred.
  • The patient died 10 years after the onset of his disease of diffuse pneumopathy with severe septicemia.
  • CASE REPORT 2: A 71-year-old man presented retroauricular basosquamous carcinoma at first treated with wide resection, but the surgical limits were invaded.
  • DISCUSSION: Basosquamous carcinoma is characterized by its severe aggression and its tendency to recur.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261262.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Wagoner J, Keehn C, Morgan MB: CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol; 2007 Dec;29(6):555-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
  • Basal cell carcinoma and squamous cell carcinoma are common entities in clinical practice.
  • We sought to determine if the CD10 immunostain could have diagnostic utility in distinguishing between early superficial basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • CD10 was negative in the tumor cells in 13 out of 13 superficially invasive SCCs and SCC in situ.
  • These findings support the utility of CD10 as a marker for early BCC, especially when SCC cannot be excluded clinically or by conventional stains.
  • Furthermore, these results implicate CD10 in the pathogenesis of BCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neprilysin / analysis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032951.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


47. Ouyang YH: Skin cancer of the head and neck. Semin Plast Surg; 2010 May;24(2):117-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer of the head and neck.
  • The majority of skin cancers of the head and neck are nonmelanoma skin cancers (NMSC).
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of NMSC.
  • Malignant melanoma is an aggressive neoplasm of skin, and the ideal adjuvant therapy has not yet been found, although various options for treatment of skin cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.
  • Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against skin cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550432.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324239
  • [Keywords] NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma
  •  go-up   go-down


48. Diepgen TL: [Epidemiology of chronic UV-damage]. J Dtsch Dermatol Ges; 2005 Sep;3 Suppl 2:S32-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas in Australia the high incidence of UV-induced skin cancer and chronic UV-damage is epidemiologically well proved, comparable figures in Europe and particularly in Germany are missing.
  • Presumably, the prevalence and incidence of actinic keratoses, basal cell carcinoma and squamous cell carcinoma are significantly underestimated.
  • The importance of chronic skin damage is discussed in accordance with new epidemiologic studies recently published in international journals.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Photosensitivity Disorders / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117742.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Erb P, Ji J, Wernli M, Kump E, Glaser A, Büchner SA: Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett; 2005 Aug 15;100(1):68-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of apoptosis in basal cell and squamous cell carcinoma formation.
  • Long-term ultraviolet-light (UV) exposure of human skin epidermis is associated with an increased risk for the development of skin cancers, such as melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • UV radiation not only induces DNA damage in epidermal cells, it also interferes with skin homeostasis, which is maintained by a unique distribution pattern of apoptosis-inducing and -preventing molecules.
  • If the DNA damage is not repaired or the damaged cells are not eliminated by apoptosis, the consequence can be cell transformation, uncontrolled proliferation and eventually skin tumor formation.
  • Excessive UV exposure can mutate the p53 gene leading to the loss of its repair function and thus apoptosis resistance of the DNA-damaged cell.
  • For BCC formation an additional pathway has been identified.
  • In addition, BCC and SCC strongly express the apoptosis-inducing Fas-ligand (FasL) which may help the tumor to escape the attack of immune effector cells.
  • Silencing the genes involved in tumor formation by RNA interference might become a promising new approach to treat skin tumors.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Gene Expression Regulation, Neoplastic / radiation effects. Signal Transduction / radiation effects. Skin Neoplasms / metabolism. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Animals. DNA Damage / genetics. DNA Damage / radiation effects. Fas Ligand Protein. Hedgehog Proteins. Humans. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Mice. Mutation. Trans-Activators / genetics. Trans-Activators / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054233.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Hedgehog Proteins; 0 / Membrane Glycoproteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 24
  •  go-up   go-down


50. Ban JH, Lee JK, Jin SM, Lee KC: Basaloid squamous cell carcinoma of the external auditory canal: case report. Eur Arch Otorhinolaryngol; 2007 Jun;264(6):697-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the external auditory canal: case report.
  • Basaloid squamous cell carcinoma (BSCC) is a rare malignancy, with features of both basal cell carcinoma and squamous cell carcinoma.
  • The tumor has a predilection for the upper aerodigestive tract, and has been suggested to behave more aggressively than squamous cell carcinoma (SCC).
  • Excision of the tumor was accomplished by modified lateral temporal bone resection.
  • This report describes the first case of BSCC in this location, and includes reviews of the pathologic and clinical aspects of this disease.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Ear Canal / pathology. Ear Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2000 Sep;110(9):1479-82 [10983946.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Nov-Dec;65(6):332-40 [14981326.001]
  • [Cites] Arch Otolaryngol. 1980 Nov;106(11):675-9 [6252880.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1179-83 [15235344.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Otolaryngol. 2005 Jun;34(3):212-5 [16089230.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2006;59(4):424-8 [16756261.001]
  • (PMID = 17235532.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Cabanillas M, Pérez-Pérez L, Sánchez-Aguilar D, Fernández-Redondo V, Toribio J: [Acrokeratosis paraneoplastica with bullous lesions associated with esophageal squamous cell carcinoma]. Actas Dermosifiliogr; 2006 Apr;97(3):196-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acrokeratosis paraneoplastica with bullous lesions associated with esophageal squamous cell carcinoma].
  • [Transliterated title] Acroqueratosis paraneoplásica con lesiones ampollosas asociada a carcinoma epidermoide esofágico.
  • Acrokeratosis paraneoplastica (Bazex syndrome) is characterized by an acral eruption with a psoriasiform appearance, which usually presents simultaneously with an underlying neoplasm.
  • We describe the case of a 64-year-old male who presented with a two-month history of pruritic, flaky, erythematous lesions on the palms, backs of the fingers and toes and pinnae, accompanied by bullous lesions.
  • The digestive endoscopy revealed a squamous cell carcinoma in the proximal esophagus.
  • The histopathological study of the bullous lesions showed the presence of a subepidermal bulla, and direct immunofluorescence revealed granular deposits of IgG, IgA and C3 in the basal membrane of the healthy perilesional skin.
  • [MeSH-major] Acrodermatitis / etiology. Blister / etiology. Carcinoma, Squamous Cell / complications. Esophageal Neoplasms / complications. Keratosis / etiology. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Deglutition Disorders / etiology. Ear, External. Fatal Outcome. Hepatic Encephalopathy / etiology. Humans. Liver Neoplasms / complications. Liver Neoplasms / secondary. Male. Middle Aged. Pleural Effusion, Malignant / etiology. Wasting Syndrome / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796967.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


52. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


53. Abenoza P, Kowalczyk J, Nousari CH: Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia. Am J Dermatopathol; 2010 Jun;32(4):348-51
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia.
  • Reactive epithelial hyperplasia is a well-known phenomenon which occurs adjacent to certain neoplasms such as cutaneous fibrous histiocytoma, granular cell tumor, Spitz nevus, and melanoma.
  • We report 46 cases of paratumoral follicular and epidermal hyperplasia associated with basal cell carcinoma (BCC).
  • This reactive process associated with BCC has certain characteristic features.
  • It may resemble other tumors such as squamous cell carcinoma and may appear in sections where BCC is absent.
  • The recognition of this entity may help dermatopathologists avoid misdiagnosing this process as a tumor and can suggest further search (section through the block or rebiopsy) when this reactive phenomenon is seen in sections without the associated BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Diseases / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2011 Feb;33(1):107 [21239900.001]
  • (PMID = 20145534.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Dawe RS: Treatment options for non-melanoma skin cancer. G Ital Dermatol Venereol; 2009 Aug;144(4):453-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for non-melanoma skin cancer.
  • Non melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) are becoming more common.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755949.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


55. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM: Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol; 2006 Aug;142(8):976-82
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial resurfacing for nonmelanoma skin cancer prophylaxis.
  • OBJECTIVE: To determine the effect of facial skin resurfacing for treatment of actinic keratoses (AKs) and prophylaxis against new primary basal and squamous cell carcinomas in individuals with previous nonmelanoma skin cancer (NMSC) or severe photodamage.
  • SETTING: Dermatology and otolaryngology clinics of a Veterans Affairs hospital.
  • PATIENTS: Thirty-four patients with a history of facial or scalp AKs or basal or squamous cell carcinoma were enrolled.
  • Times from baseline to diagnosis of first skin cancer were compared between the treatment and control groups.
  • RESULTS: Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =.03), a lower incidence of NMSC compared with the control group (P<.001), and a trend toward longer time to development of new skin cancer compared with the control group (P=.07).
  • CONCLUSION: All 3 modalities demonstrated benefit for AK reduction and skin cancer prophylaxis compared with controls and warrant further study in a larger trial.
  • [MeSH-major] Keratolytic Agents / administration & dosage. Keratosis / prevention & control. Low-Level Light Therapy. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Carbon Dioxide. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / prevention & control. Disease-Free Survival. Drug Administration Schedule. Face. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Prospective Studies. Scalp. Severity of Illness Index. Treatment Outcome. Trichloroacetic Acid / administration & dosage


56. Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N: The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose. Med J Malaysia; 2008 Oct;63(4):339-40
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
  • Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.
  • The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.
  • Excision of the BCC will leave the nose with a soft tissue defect which requires reconstruction.
  • This report illustrates a case of BCC of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385500.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


57. Gass JK, Chan SK, Rytina E, Greenberg DC, Burrows NP: Multiple primary malignancies in patients with Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2010 May;24(5):601-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies in patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing.
  • OBJECTIVES: We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke's Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC.
  • RESULTS: The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years.
  • Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC.
  • Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non-cutaneous malignancy including colorectal, haematological and breast tumours.
  • Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis.
  • CONCLUSIONS: Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Neoplasms, Multiple Primary / complications. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900177.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Massari LP, Kastelan M, Gruber F: Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol; 2007 Jan;31 Suppl 1:83-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
  • Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most common malignant tumors in humans.
  • Basal cell carcinoma grows slowly and metastatic spread is very rare.
  • Squamous cell carcinoma is characterized by infiltrative, destructive growth and metastasis.
  • Long-term exposure of skin to UV light has a great impact on development of these epidermal malignancies.
  • The major role in development of skin cancer is given to proapoptotic p53 molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to apoptosis.
  • Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by the ability of tumor to escape the attack of immune system.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Neoplasms, Radiation-Induced / physiopathology. Skin Neoplasms / physiopathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469758.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 29
  •  go-up   go-down


59. Kolm I, Hofbauer G, Braun RP: [Early diagnosis of skin cancer]. Ther Umsch; 2010 Sep;67(9):439-46
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of skin cancer].
  • The skin is the most affected organ by cancer.
  • The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).
  • Over 90 % of the death cases from skin cancers attribute to melanoma.
  • In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.
  • In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.
  • Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806172.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


60. Emanuel P, Wang B, Wu M, Burstein DE: p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol; 2005 May;18(5):645-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma.
  • Morphologic distinction of high-grade adenoid cystic carcinoma from basaloid squamous cell carcinoma can be difficult.
  • We have investigated the possibility that immunohistochemical staining for the presence of p63, a novel epithelial stem-cell regulatory protein, could be a useful means of distinguishing these two neoplasms.
  • Archival, routinely processed slides were subjected to citrate-based antigen retrieval, exposure to anti-p63 monoclonal 4A4, and developed with a streptavidin-biotin kit and diaminobenzidine as chromogen. p63 was detected in 100% of the adenoid cystic carcinomas (n=14) and 100% of basaloid squamous cell carcinomas (n=16).
  • Basaloid squamous cell carcinomas consistently displayed diffuse p63 positivity, with staining of nearly 100% of tumor cells.
  • In contrast, adenoid cystic carcinoma displayed a consistently compartmentalized pattern within tumor nests.
  • (1) selective staining of a single peripheral layer of p63-positive cells surrounding centrally located tumor cells that were p63-negative and (2) tumor nests consisting of multiple contiguous glandular/cribriform-like units of p63-positive cells surrounding or interspersed with p63-negative cells. p63 immunostaining constitutes a specific and accurate means of distinguishing adenoid cystic carcinoma from basaloid squamous cell carcinoma. p63 positivity in adenoid cystic carcinoma appears to be homologous to that seen in the basal and/or myoepithelial compartments of salivary gland and other epithelia, and may signify a stem-cell-like role for these peripheral cells.
  • Diffuse p63 positivity in basaloid squamous cell carcinoma suggests dysregulation of p63-positive stem cells in poorly differentiated squamous carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Phosphoproteins / analysis. Trans-Activators / analysis
  • [MeSH-minor] DNA-Binding Proteins. Diagnosis, Differential. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529180.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


61. Kim GK, Del Rosso JQ, Bellew S: Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2009 Aug;2(8):39-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer in asians: part 1: nonmelanoma skin cancer.
  • Since the 1960s, basal cell carcinoma and squamous cell carcinoma among the Caucasian population have increased 3 to 8 percent annually.
  • Although Asians display relative protection from basal cell carcinoma and squamous cell carcinoma, incidence rates of these nonmelanoma skin cancers have been increasing over the past three decades.
  • With changing demographics and a steady rise in the minority population in the United States, there is an increased need for further studies of cutaneous malignancies within Asian and other ethnic populations.
  • This article reviews nonmelanoma skin cancers in the Asian population with an insight into contributing factors, such as skin type, occupation, cultural practices, and genetic components.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):63-6 [18173702.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]
  • [Cites] Photochem Photobiol Sci. 2006 Feb;5(2):208-14 [16465307.001]
  • [Cites] Ann Surg. 1965 Feb;161:170-88 [14260013.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):86-94 [10456656.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):843-4 [10411160.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Dermatol. 1984 Aug;11(4):313-21 [6392379.001]
  • [Cites] J Dermatol. 1990 Jun;17(6):342-6 [2384636.001]
  • [Cites] Plast Reconstr Surg. 1978 Sep;62(3):407-14 [693668.001]
  • [Cites] Ann Dermatol Venereol. 2003 Apr;130(4):413-6 [12843850.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):841-8 [11298546.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S14-21 [10709346.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):781-6 [10411152.001]
  • [Cites] J Dermatol Sci. 1999 Apr;19(3):161-5 [10215187.001]
  • [Cites] J Dermatol Sci. 1997 Nov;16(1):74-8 [9438911.001]
  • [Cites] J Dermatol Sci. 1997 Sep;15(3):183-7 [9302646.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Feb;12(1):22-6 [8884895.001]
  • [Cites] J Trauma. 1997 Jan;42(1):104-7 [9003266.001]
  • [Cites] Am J Dermatopathol. 2006 Dec;28(6):472-7 [17122490.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • [Cites] Dermatol Clin. 1995 Jul;13(3):583-94 [7554506.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):440-4 [8151121.001]
  • [Cites] Recent Results Cancer Res. 1995;139:263-73 [7597297.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • (PMID = 20729955.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923966
  •  go-up   go-down


62. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


63. Hatta N, Hirano T, Kimura T, Hashimoto K, Mehregan DR, Ansai S, Takehara K, Takata M: Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels. J Cutan Pathol; 2005 Feb;32(2):131-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels.
  • BACKGROUND: Distinguishing basal cell carcinoma (BCC) from other benign and malignant skin tumors is sometimes a difficult task for the pathologists.
  • Because the activation of hedgehog signals and the up-regulation of its critical transcriptional factor Gli1 are well documented in BCC, a molecular technique measuring Gli1 transcripts may aide the diagnosis.
  • METHODS: Gli1 transcript levels were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using RNA extracted from formalin-fixed, paraffin-embedded tissues of 68 cases of various skin tumors.
  • The tumors included BCC (21), squamous cell carcinoma (13), seborrheic keratoses (8), trichoepithelioma (5), eccrine poroma/porocarcinoma (4), and sebaceous epithelioma/carcinoma (2).
  • In these unambiguous cases, all BCC and trichoepithelioma tumors showed high expression of Gli1mRNA, while the expression was virtually absent in other tumors.
  • The diagnosis was discordant among three pathologists in the remaining 15 tumors.
  • Histological diagnoses included BCC, BCC with sebaceous differentiation, sebaceoma/sebaceous epithelioma, trichoblastoma, trichoepithelioma, basaloid follicular harmartoma, basosquamous carcinoma, etc.
  • CONCLUSIONS: Quantification of Gli1 transcripts by RT-PCR is helpful in discriminating BCC and trichoepithelioma from other skin tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Oncogene Proteins / metabolism. Skin Neoplasms / diagnosis. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606671.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gli protein; 0 / Oncogene Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


64. Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, Ficsor L, Molnar B, Kopper L, Krenacs T: Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):433-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy.
  • Collagen XVII/BP180, a hemidesmosomal adhesion protein, is lost during normal keratinocyte maturation; however, it may be reexpressed upon malignant transformation.
  • In this work, highly sensitive monoclonal antibodies 6D1 and 9G2 were produced, characterized, and used for the detection of collagen XVII in a tissue microarray series of archived samples of nonmelanocytic epithelial neoplasias, including 5 verruca vulgaris, 14 seborrheic keratosis, 38 actinic keratosis, 38 basal cell carcinoma (BCC), 15 basosquamous carcinoma, 58 squamous cell carcinoma (SCC), and 9 normal skin.
  • Digital microscopy and a new tissue microarray software linking image and patient data allowed easy and validated evaluation and quality archiving of stained samples.
  • In normal skin and benign epidermal lesions, collagen XVII protein was restricted to basal keratinocytes.
  • However, possibly as a sign of undifferentiated/transformed state, it was widely expressed in SCC showing elevated levels around invasive tumor fronts with some staining in tumor adjacent stroma, endothelium, and histiocytes.
  • Squamous component of basosquamous carcinoma showed moderate reaction, whereas islets of BCC were mainly negative reflecting the diverse genotype and phenotype, and pathogenesis of SCC and BCC.
  • These results suggest that collagen XVII neoexpression may be associated with early atypia/malignant transformation of keratinocytes.
  • Further investigations are under way to analyze the potential of these antibodies for tracing progression and metastatic potential of skin tumors.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633319.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Non-Fibrillar Collagens; 0 / collagen type XVII
  •  go-up   go-down


65. Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Feb;52(2):295-300
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is reported to have a high rate of recurrence with standard wide local excision.
  • METHODS: This prospective, multi-center case series included all patients in Australia treated with MMS for MAC, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 31.8% of cases it was a recurrent tumor.
  • In 32.5% of cases the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692477.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


66. Park K, Lee JH: Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation. Oncol Rep; 2009 Mar;21(3):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation.
  • There is considerable evidence that the excessive ultraviolet radiation B (UVB) from sunlight is implicated in skin damage, ultimately inducing the death of keratinocytes.
  • If the apoptotic pathway does not work properly, the damaged cells have a chance to transform into a carcinoma, such as basal cell carcinoma or squamous cell carcinoma of the skin.
  • To develop a strategy of inducing apoptosis of skin cancer cells, the current study was performed to investigate the apoptotic pathway, especially focused on Bcl2 family proteins, in curcumin or UVB-treated basal cell carcinoma cell lines.
  • Our data demonstrated that the expression of Bcl-XL protein was decreased by proteasome-mediated degradation prior to change of mRNA level in UVB-induced apoptotic basal cell carcinoma cell lines, thereby these results will offer fundamental information to develop a strategy of inducing apoptosis of skin cancer cells.
  • [MeSH-major] Apoptosis / radiation effects. Carcinoma, Basal Cell / metabolism. Proteasome Endopeptidase Complex / radiation effects. bcl-X Protein / radiation effects
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Proliferation / radiation effects. Curcumin / pharmacology. DNA Fragmentation. Gene Expression / radiation effects. Humans. Reverse Transcriptase Polymerase Chain Reaction. Ultraviolet Rays. bcl-2-Associated X Protein / radiation effects. bcl-Associated Death Protein / radiation effects

  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212627.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / bcl-2-Associated X Protein; 0 / bcl-Associated Death Protein; 0 / bcl-X Protein; EC 3.4.25.1 / Proteasome Endopeptidase Complex; IT942ZTH98 / Curcumin
  •  go-up   go-down


67. Decara JM, Aguilera J, Abdala R, Sánchez P, Figueroa FL, Herrera E: Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin. Exp Dermatol; 2008 Oct;17(10):806-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin.
  • This immunomodulation has been recognized as an important factor related to skin cancer development.
  • This is the first time that UCA isomers have been measured in epidermis of skin biopsies from patients with squamous cell carcinoma (SCC) and with basal cell carcinoma (BCC) and compared with the tumor periphery and biopsies of healthy photoexposed and non-photoexposed skin as controls.
  • Analysis of UCA in healthy skin showed significant increase in total UCA content in non-photoexposed body sites compared with highly exposed skins.
  • No differences were found in total UCA concentration between the tumor samples and healthy photoexposed skin.
  • Higher levels of cUCA were detected in SCC biopsies (44% of total UCA) compared with samples of BCC and that of healthy photoexposed skin (30%).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Epidermis / radiation effects. Skin Neoplasms / pathology. Ultraviolet Rays. Urocanic Acid / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312386.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] G8D26XJJ3B / Urocanic Acid
  •  go-up   go-down


68. Hassanein AM, Proper SA, Depcik-Smith ND, Flowers FP: Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery. Dermatol Surg; 2005 Sep;31(9 Pt 1):1101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery.
  • BACKGROUND: Perineural invasion (PI) in cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) is linked to an aggressive course.
  • OBJECTIVE: To describe the morphologic changes associated with PF and to determine the incidence of PF and PI in Mohs frozen sections of BCC and SCC.
  • MATERIAL AND METHODS: All cases of BCC and SCC that were treated by Mohs micrographic surgery (MMS) at the Skin and Cancer Center, University of Florida College of Medicine, Gainesville, Florida, and the Center for Dermatology and Skin Surgery, Tampa, Florida, during the period from January 1, 2003, to August 1, 2004, were reviewed for the presence of PI and PF.
  • The latter was defined as the presence of concentric layers of fibrous tissue that either surround and/or were surrounded by tumor formations mimicking perineural or intraneural invasion.
  • Seven hundred six cases of BCC and 264 cases of SCC were surveyed.
  • Eleven cases (10 BCC and 1 SCC) with equivocal areas were destained, and immunohistochemical staining with S-100 protein was performed, proving actual PI in all of these cases.
  • The incidence of unequivocal PI was noted to be 2.6% in SCC and 2.1% in BCC.
  • CONCLUSION: We describe a specific pattern of fibrosis noted in BCC and SCC that we called PF.
  • It shows concentric layers of fibrous tissue surrounding and/or surrounded by tumor formations and resembles carcinomatous perineural and/or intraneural invasion.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fibrosis / pathology. Humans. Mohs Surgery. Neoplasm Invasiveness


69. Weinstock MA: Controversies in the public health approach to keratinocyte carcinomas. Br J Dermatol; 2006 May;154 Suppl 1:3-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the public health approach to keratinocyte carcinomas.
  • Keratinocyte carcinomas are very common cancers in fair-skinned populations throughout the world.
  • The term 'keratinocyte carcinoma' includes basal and squamous cell carcinoma of the skin, but not other cancers that may be included under the more ambiguous term 'nonmelanoma skin cancer'.
  • Mortality from keratinocyte carcinoma reveals distinct patterns suggestive of an important role of human papilloma virus infection.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712708.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 12
  •  go-up   go-down


70. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M: Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev; 2010 Nov;19(11):2942-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitizing medication use and risk of skin cancer.
  • Whether use of these medications affects skin cancer risk, however, is unclear.
  • METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma.
  • RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively.
  • In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers.
  • CONCLUSION: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer.
  • Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.
  • [MeSH-major] Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


71. Leiter U, Garbe C: [Skin cancer in organ transplant patients. Epidemiology and management]. Hautarzt; 2010 Mar;61(3):207-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancer in organ transplant patients. Epidemiology and management].
  • Skin cancer is the most common cancer, representing 40-50% of post transplant malignancies.
  • In the first 10 years post transplantation, some 15%-40% of patients develop skin cancer, primarily squamous cell carcinoma and basal cell carcinoma, but also melanoma, Merkel cell carcinoma and virally-induced Kaposi sarcoma.
  • The management of skin cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.
  • In high risk skin cancer or metastatic disease a substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.
  • The management of the individual tumor types is discussed; in general it follows the current guidelines.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2008 Apr;18(2):152-60 [18337653.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6 [18801136.001]
  • [Cites] Am J Transplant. 2008 Sep;8(9):1891-900 [18786232.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):232-7 [19370807.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4 [18801139.001]
  • [Cites] ScientificWorldJournal. 2008 Sep 21;8:909-19 [18836658.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] Transplantation. 2009 Aug 27;88(4):597-8 [19696647.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):1-12 [17520670.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1567-72 [19681993.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1792-3 [17198278.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24 [18801138.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14 [18801142.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):510-1 [18679393.001]
  • [Cites] J Am Acad Dermatol. 2008 Sep;59(3):405-17 [18556089.001]
  • [Cites] Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92 [3388524.001]
  • [Cites] Melanoma Res. 2008 Feb;18(1):61-7 [18227710.001]
  • [Cites] Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15 [19680830.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):451-4 [16882188.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6 [17379490.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1183-8 [17916206.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • (PMID = 20145902.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


72. Zemtsov A: Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer. Arch Dermatol Res; 2010 Apr;302(3):169-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer.
  • A case of a patient, with MMD multiple basal and squamous cell carcinomas and dysplastic nevi, is described.
  • The association between MMD and non-melanoma skin cancer has been reported before; however, this association was described before the genetic defect of myotonic dystrophy has been fully elucidated.
  • The author proposes a genetic mechanism on how abnormal function of RBP can result or contribute to the development of human skin cancer and propose an explanation for this association between MMD and cutaneous carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic / genetics. Dysplastic Nevus Syndrome / genetics. Myotonic Dystrophy / genetics. RNA-Binding Proteins / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. DNA Damage. DNA Repair. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Humans. Male. Risk Factors

  • Genetic Alliance. consumer health - Muscular dystrophy.
  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902230.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; News
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA-Binding Proteins
  •  go-up   go-down


73. Nieto Enriquez J, Medel Jiménez R, Huguet Redecilla P: Undiagnosed squamous cell carcinoma of the forehead presenting as a Tolosa-Hunt syndrome. Orbit; 2009;28(5):290-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undiagnosed squamous cell carcinoma of the forehead presenting as a Tolosa-Hunt syndrome.
  • Squamous cell carcinoma (SCC) is the second most common periocular skin cancer.
  • We describe a case of invasive squamous cell carcinoma arising from actinic keratosis and causing orbital and intracranial invasion via perineural spread.
  • Perineural invasion (PNI) is a known feature of SCC and very rarely basal cell carcinomas of the head and neck.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Skin Neoplasms / diagnosis. Tolosa-Hunt Syndrome / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Forehead. Humans. Keratosis, Actinic / complications. Neoplasm Invasiveness


74. Dixon A, Rosengren H, Connelly T, Dixon J: Education in skin cancer management--assessing knowledge and safety. Aust Fam Physician; 2009 Jul;38(7):557-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education in skin cancer management--assessing knowledge and safety.
  • BACKGROUND: General practitioners manage the majority of skin cancers in Australia.
  • There are a range of training opportunities for, and certifications in, skin cancer management.
  • METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College of Skin Cancer Medicine website.
  • Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma, basal cell carcinoma and squamous cell carcinoma.
  • Two days of training may not make doctors sufficiently safe in skin cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.
  • [MeSH-major] Family Practice / education. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575076.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


75. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • Interleukin-6 concentrations were higher in aggressive BCC variants (infiltrative and micronodular), but the difference was not statistically significant (p = 0.068).
  • CONCLUSIONS: Confirming the earlier findings that BCC is a tumor with a Th2 cytokine microenvironment, this study further shows that BCC situated on the head and neck produce even more of certain Th2 cytokines (IL-4 and IL-5) and TNF-alpha, a crucial immunosuppressive cytokine released upon UVB irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


76. Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S: Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res; 2007 Jan-Feb;27(1B):547-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
  • BACKGROUND: Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour.
  • PATIENTS AND METHODS: Twenty-seven cases of SCC (pure or not) of the breast were matched with 27 ductal invasive carcinomas (IDC) for age, tumour size, nodal involvement and year of diagnosis.
  • RESULTS: Pure and metaplastic SCC displayed common profiles typifying a basal origin: they never expressed ER or PR, were HER2-negative in 93% of cases, exhibited positivity for CK5/6 or EGF-R in 75% and 85%, and for p63 in 70% of cases and were highly proliferative.
  • A typical "basal-like" phenotype was displayed that may explain part of their behaviour and justify specific therapeutic approaches.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Squamous Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alphapapillomavirus / genetics. Cohort Studies. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Keratin-5 / analysis. Keratin-6 / analysis. Ki-67 Antigen / analysis. Middle Aged. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Polymerase Chain Reaction. Receptor, Epidermal Growth Factor / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Survival Analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins / analysis


77. Chow KC, Lu MP, Wu MT: Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J Dermatol Sci; 2006 Mar;41(3):205-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma.
  • Previous clinical studies have demonstrated the over-expression of DDH in various types of cancers, including cutaneous squamous cell carcinoma (SCC), and its correlation with tumor progression and grave prognosis.
  • OBJECTIVE: To investigate possible mechanisms for DDH's correlation with tumor progression and unfavorable prognosis.
  • METHODS: DDH expression in SCC A431 cell line was examined by quantitative real-time PCR and immunoblotting.
  • RESULTS: DDH was found highly expressed by SCC A431 cells, which was barely detectable in other normal or malignant cutaneous cells, including keratinocytes, fibroblast, and basal cell carcinoma cell line.
  • CONCLUSION: DDH may play important roles in tumor progression of SCC via induction of apoptosis- and drug-resistance.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Oxidoreductases / biosynthesis
  • [MeSH-minor] Bleomycin / pharmacology. Caspase 3. Caspases / metabolism. Cell Line. Cell Line, Tumor. Disease Progression. Fibroblasts / metabolism. Humans. In Situ Nick-End Labeling. Keratinocytes / metabolism. Models, Statistical. Polycyclic Hydrocarbons, Aromatic / metabolism. Prognosis. RNA Interference. Skin Neoplasms / drug therapy. Skin Neoplasms / enzymology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Ultraviolet Rays. Up-Regulation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361083.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Tetrazolium Salts; 0 / Thiazoles; 11056-06-7 / Bleomycin; 298-93-1 / thiazolyl blue; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


78. Hantschmann P, Sterzer S, Jeschke U, Friese K: P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. Anticancer Res; 2005 May-Jun;25(3A):1739-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus.
  • BACKGROUND: p53 inactivation due to oncogenic viral proteins or mutations is an important molecular mechanism in carcinogenesis, which has also been demonstrated for vulvar carcinoma.
  • To evaluate p53 changes in vulvar carcinogenesis, we analyzed p53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia (VIN), lichen sclerosus (LS) and squamous cell hyperplasia (SH).
  • PATIENTS AND METHODS: Seventy-three carcinomas, 141 cases of VIN, 55 biopsies of LS with 8 associated to carcinoma, 57 cases of SH with 14 associated to carcinoma and 10 cases without neoplastic changes were stained immunohistologically for p53.
  • RESULTS: Normal vulvar epithelium showed low p53 staining in the basal epithelial layers.
  • Forty % of LS and SH not associated to carcinoma showed immunohistological signs of p53 mutation, while cases associated with carcinoma did so in 90%.
  • Sixty-seven % of the carcinomas showed immunohistological changes of p53 expression.
  • Tumors with low p53 expression were significantly associated with patients younger than 50 years (p<0.01) and basaloid or condylomatous tumor type (p<0.015).
  • There were three different patterns of p53 staining, which were significantly correlated with tumor type (p<0.01).
  • CONCLUSION: p53 mutations are present in typical keratinizing carcinomas, precursor lesions and disorders with elevated risk for vulvar cancer.
  • Thus, p53 mutation seems to occur early in vulvar carcinogenesis and may become a useful marker, especially in lesions with increased risk of carcinoma.
  • [MeSH-major] Carcinoma in Situ / metabolism. Hyperplasia / metabolism. Lichen Sclerosus et Atrophicus / metabolism. Tumor Suppressor Protein p53 / metabolism. Vulvar Neoplasms / metabolism


79. Chovanec M, Smetana K Jr, Plzák J, Betka J, Plzáková Z, Stork J, Hrdlicková E, Kuwabara I, Dvoránková B, Liu FT, Kaltner H, André S, Gabius HJ: Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med Rep; 2005;106(2):209-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.
  • Lectins represent one of pivotal regulators of the cell proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed squamous epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma, basal and squamous cell carcinoma) and endodermal (vocal fold epithelium vs. carcinoma) origin.
  • Its expression is significantly reduced in malignant cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epithelium / chemistry. Galectins / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Division / physiology. Cells, Cultured. Humans. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315769.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


80. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA, EPI-HPV-UV-CA group: Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol; 2007 Jul;127(7):1647-56
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
  • This study examines the association of keratotic skin lesions with the development of skin cancer in 915 solid organ-transplant recipients in five European countries.
  • In a hospital-based case-control study, cases with squamous- and basal-cell carcinoma were compared with controls without skin cancer.
  • Questionnaires, scrutiny of medical charts, and skin examination were delivered according to a standardized protocol.
  • Keratotic skin lesions and viral warts were counted on different body sites.
  • Keratotic skin lesions were strongly associated with an increased risk of squamous-cell carcinoma, with adjusted odds ratios of 4.1 (2.4;7.0) and 12.1 (6.1;24) for 1-49 and 50 and more keratotic skin lesions compared with no lesions, respectively.
  • Keratotic skin lesions were also associated with basal-cell carcinoma with adjusted odds ratios of 2.9 (1.7;4.9) and 4.0 (1.7;9.2) for 1-49 and 50 and more lesions, respectively.
  • Lighter skin types and painful sunburns were also significantly associated with an increased risk of squamous- and basal-cell carcinoma.
  • Keratotic skin lesions are strongly associated with skin cancer and are, thus, an important clinical criterion for identifying those organ-transplant recipients at an increased risk of skin cancers who should be offered more intensive skin surveillance.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Keratosis / pathology. Skin Neoplasms / etiology. Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Papillomavirus Infections / epidemiology. Risk Factors. Sex Characteristics. Skin Pigmentation. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99 [15979889.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2087-96 [10834958.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] Transplantation. 2000 Nov 27;70(10):1479-84 [11118094.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):231-8 [11134217.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4741-8 [12198176.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):950-6 [12410706.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Acta Derm Venereol. 2003;83(3):189-93 [12816154.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Arch Dermatol Res. 2003 Dec;295(7):273-9 [14618345.001]
  • [Cites] J Invest Dermatol. 2003 Dec;121(6):1531-5 [14675206.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1540-3 [14693751.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2639-42 [15215478.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):93-7 [15982308.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Invest Dermatol. 1995 Sep;105(3):367-71 [7665914.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] N Engl J Med. 1991 Sep 19;325(12):843-8 [1875968.001]
  • [Cites] Acta Derm Venereol. 1990;70(6):491-4 [1981421.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Q J Med. 1987 Jul;64(243):609-16 [3313494.001]
  • [Cites] Lancet. 1984 Mar 31;1(8379):702-5 [6143041.001]
  • (PMID = 17380113.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2478722; NLM/ UKMS1916
  •  go-up   go-down


81. Ishihara K: [Reasons for the increased incidence of skin cancer]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1380-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reasons for the increased incidence of skin cancer].
  • The cutaneous malignancies with an increasing incidence in Japan are squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.
  • According to a nationwide questionnaire survey (responses from 94 centers), basal cell carcinoma has the highest incidence and accounts for nearly 50% of all skin malignancies, followed by squamous cell carcinoma (31%) and malignant melanoma (21%).
  • The number of cases of each tumor has grown annually, and comparison of the percent increases between 1987 and 2001 shows an increase of about 1.5-fold for basal cell carcinoma or 1.7-fold for squamous cell carcinoma or malignant melanoma.
  • Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, the Malignant Skin Tumor Research Group has been investigating the factors behind these increases by detailed statistical analysis of data obtained from 1987 onwards from designated centers (19-22 centers).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033224.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma Pigmentosum (XP) is a photosensitive skin disease with a high risk for developing skin malignancy.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


83. Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N: Metatypical basal cell carcinoma: a clinical review. J Exp Clin Cancer Res; 2008;27:65
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metatypical basal cell carcinoma: a clinical review.
  • BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.
  • The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.
  • It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.
  • METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.
  • CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]
  • [Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]
  • [Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]
  • [Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]
  • [Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]
  • [Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]
  • [Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]
  • [Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]
  • [Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]
  • [Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]
  • [Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]
  • (PMID = 18992138.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2585560
  •  go-up   go-down


84. Mitsuhashi T, Itoh T, Shimizu Y, Ban S, Ogawa F, Hirose T, Shimizu M: Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol; 2006 Mar;33(3):246-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants.
  • Basosquamous carcinoma (BSC) is defined as a tumor containing the areas of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with a transition zone linking the two.
  • Spindle cell squamous carcinoma (SCSC) may have a variable component of conventional SCC and spindle cells.
  • Grossly, the lesion measured 8.5 x 6.0 x 1.8 cm and consisted of a gray-white and focally black tumor.
  • Microscopically, a non-ulcerated upper part of the tumor consisted of large polygonal squamoid cells with occasional keratinization (SCC), trabecular growth of basaloid cells with peripheral palisading (BCC), and an area in which both the components were intermingled.
  • The rest of the tumor was a myxoid area with elongated fusiform spindle cells, which appeared to arise from conventional SCC.
  • Immunohistochemically, the tumor cells in the SCSC (both conventional and spindle cell) area co-expressed CAM5.2, and vimentin.
  • Ber-EP4 was positive in the BCC area with the transition zone of SCC and BCC showing diminished staining.
  • To our knowledge, this is the first case report of SCC of the skin that has dual differentiations to BSC and SCSC.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466514.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA: Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther; 2005 Jan-Feb;18(1):77-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.
  • This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.
  • [MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842615.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 148
  •  go-up   go-down


86. Cunneen TS, Yong JL, Benger R: Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Exp Ophthalmol; 2008 Jul;36(5):475-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential.
  • Basal cell carcinoma (BCC) is an extremely common malignancy; however, unlike other skin cancers, they very rarely metastasize.
  • Here we present an unusual case of metatypical BCC of the eyelid which metastasized to the lung nine years after initial surgical treatment.
  • We include a review of the literature regarding metastatic BCC and suggest that metatypical features in primary BCC should prompt careful patient monitoring and consideration of adjuvant treatment at the time of diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Lung Neoplasms / pathology. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18925916.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 13
  •  go-up   go-down


87. Dim-Jamora KC, Perone JB: Management of cutaneous tumors with mohs micrographic surgery. Semin Plast Surg; 2008 Nov;22(4):247-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the use of Mohs micrographic surgery for the following cutaneous tumors: basal cell carcinoma, squamous cell carcinoma, melanoma in situ, dermatofibrosarcoma protuberans, Merkel cell carcinoma, microcystic adnexal carcinoma, atypical fibroxanthoma, and sebaceous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Mar 16;347(9003):735-8 [8602006.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):233-6 [7829708.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):433-4 [7905951.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2964-70 [8199993.001]
  • [Cites] Clin Plast Surg. 1993 Jan;20(1):149-56 [8420703.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):840-5 [8408823.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Apr;26(2):185-202 [8460037.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Aug;17(8):681-4 [1885833.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):833-43 [2676291.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):609-11 [2676280.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] N J Med. 1989 May;86(5):369-73 [2739948.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):668-73 [3958277.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 1):160-8 [2323467.001]
  • [Cites] Head Neck Surg. 1983 Jan-Feb;5(3):197-203 [6841116.001]
  • [Cites] Arch Dermatol. 1974 Aug;110(2):231-2 [4853214.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2233; author reply 2233-4 [15253235.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Clin Plast Surg. 2004 Jan;31(1):5-31 [15022790.001]
  • [Cites] Plast Reconstr Surg. 2002 Nov;110(6):1601 [12409793.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):656-65 [12174054.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):336-40 [12170436.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):579-86 [11568750.001]
  • [Cites] Arch Facial Plast Surg. 2001 Jul-Sep;3(3):202-6 [11497507.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1004-9 [11369914.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):771-84 [10940065.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):303-7 [10759814.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):395-402 [17430372.001]
  • [Cites] Skin Therapy Lett. 2007 Mar;12(2):6-9 [17393051.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):187-92 [17140665.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Dermatol Surg. 2005 Nov;31(11 Pt 1):1428-33 [16416612.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 1):1094-9; discussion 1100 [16164856.001]
  • [Cites] Curr Surg. 2005 Sep-Oct;62(5):518-26 [16125611.001]
  • [Cites] Arch Facial Plast Surg. 2005 Sep-Oct;7(5):342-6 [16172346.001]
  • [Cites] J Craniofac Surg. 2005 May;16(3):439-43 [15915111.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):10-5 [15720088.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1479-85 [15606735.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Am J Otolaryngol. 2004 Nov-Dec;25(6):385-93 [15547806.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):80-95 [9669602.001]
  • [Cites] J Am Acad Dermatol. 1998 Jul;39(1):79-97 [9674401.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1061-6 [9391565.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Dermatol Surg. 1997 Feb;23(2):105-10 [9107284.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • (PMID = 20567701.001).
  • [ISSN] 1536-0067
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2884874
  • [Keywords] NOTNLM ; Mohs micrographic surgery / cutaneous oncology / skin cancer
  •  go-up   go-down


88. Vasudev P, Boutross-Tadross O, Radhi J: Basaloid squamous cell carcinoma: two case reports. Cases J; 2009;2:9351
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: two case reports.
  • Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.
  • BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]
  • [Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • (PMID = 20062602.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804002
  •  go-up   go-down


89. Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D: Photochemoprevention of cutaneous neoplasia through natural products. Exp Oncol; 2009 Mar;31(1):9-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human tumors, representing 30% of the new cases of malignancies diagnosed each year.
  • Ultraviolet radiation (UV) from the sun is a major cause of non-melanoma skin cancer in humans.
  • Here we review the progress in the research of new and existing agents developed to protect the skin exposed to UV.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cat's Claw. Flavonoids / therapeutic use. Phenols / therapeutic use. Phytotherapy. Polypodium. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300410.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polyphenols; 0 / Silymarin; 4RKY41TBTF / silybin
  • [Number-of-references] 62
  •  go-up   go-down


90. Basile J, Thiers B, Maize J Sr, Lathers DM: Chemokine receptor expression in non-melanoma skin cancer. J Cutan Pathol; 2008 Jul;35(7):623-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in non-melanoma skin cancer.
  • Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
  • However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.
  • METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.
  • RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.
  • CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
  •  go-up   go-down


91. Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett; 2008 May 8;263(1):89-98
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma.
  • Annexin A2 is a highly expressed gene with important roles in cell membrane physiology and is frequently dysregulated in cancer.
  • The objective of this study was to determine the pattern of expression and prognostic significance of annexin A2 protein in head and neck squamous cell carcinoma.
  • Annexin A2 expression was confined to the basal and suprabasal cells of normal epithelium and the protein cellular location was consistently observed at the cell membrane.
  • We conclude that annexin A2 exhibits a characteristic pattern of expression, distinct from other annexins and suggestive of a cell-specific functional role.
  • [MeSH-major] Annexin A2 / metabolism. Carcinoma, Squamous Cell / metabolism. Down-Regulation. Head and Neck Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262347.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Annexin A2
  •  go-up   go-down


92. Schulte KW, Lippold A, Auras C, Bramkamp G, Breitkopf C, Elsmann HJ, Habenicht EM, Jasnoch V, Müller-Pannes H, Rupprecht R, Suter L: Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol; 2005 Dec;53(6):993-1001
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas.
  • BACKGROUND: We have used a schedule for soft x-ray therapy of epithelial malignancies that takes into account the clinically diagnosed tumor involution under treatment.
  • METHODS: Patients with 1267 consecutively irradiated (1988-1992) basal cell and squamous cell carcinomas were followed up (average 77 months).
  • RESULTS: The recurrence rate (5.1%) was related to tumor size and thickness and to the time-dose-fractionation factor.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310060.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol; 2005 Sep;14(9):709-18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines.
  • Tumor-stroma interactions play a decisive role in the growth and metastasis of solid tumors, and involve signalling either by soluble mediators or direct cell-cell interaction.
  • Here, we report the isolation and characterisation of a novel cDNA (MEL4B3), which is induced in cultured dermal fibroblasts exposed to supernatants of melanoma cell lines.
  • In situ hybridisation revealed the expression of MEL4B3 in malignant melanoma increasing with tumor depth; in basal cell carcinoma and in squamous cell carcinoma.
  • MEL4B3 was barely detectable in normal skin or non-malignant melanocytic naevi.
  • Furthermore, MEL4B3 was expressed at high level in the epidermis of psoriatic skin.
  • In vitro, the expression of MEL4B3 was found to be induced by the exposure of human dermal fibroblasts to melanoma cell culture supernatants or to transforming growth factor-beta, interleukin-1 and tumor necrosis factor-alpha.
  • The expression MEL4B3 therefore reflects closely cell activation occurring during tumor growth, metastasis and inflammation.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Northern. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Cells, Cultured. Culture Media / metabolism. Culture Media / pharmacology. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. DNA, Complementary / metabolism. Fibroblasts / metabolism. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Inflammation. Keratinocytes / metabolism. Microcirculation. Molecular Sequence Data. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Complementary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098131.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / DNA, Complementary; 0 / FNDC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


94. Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J: Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep; 2005 Jan;13(1):151-5
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses, squamous cell carcinomas or basal cell carcinomas by specific enzyme-linked immunobiological assays.
  • The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses, squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583817.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
  •  go-up   go-down


95. Bugatti L, Filosa G: Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases. Clin Exp Dermatol; 2009 Dec;34(8):e898-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC).
  • AFX may be added to the list of slightly pigmented, reddish, malignant cutaneous tumours, such as SCC, MCC, amelanotic/hypomelanotic melanoma and eccrine porocarcinoma, which display prominent and chaotic dermatoscopic neoangiogenetic features in more advanced stages of proliferation.
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055861.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Abdulla FR, Kerns MJ, Mutasim DF: Amelanotic lentigo maligna: a report of three cases and review of the literature. J Am Acad Dermatol; 2010 May;62(5):857-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Amelanotic lentigo maligna is not clinically suspected and is often mistaken for a basal cell carcinoma, squamous cell carcinoma, or dermatitis.
  • CONCLUSION: A high degree of clinical and histologic suspicion is required to make the diagnosis of this clinically nondescript neoplasm.
  • [MeSH-major] Hutchinson's Melanotic Freckle / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Forearm. Humans. Keratosis, Actinic / diagnosis. Male. Middle Aged. Neck

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 19766347.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


97. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basosquamous carcinoma: treatment with Mohs micrographic surgery. Cancer; 2005 Jul 1;104(1):170-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare tumor defined as a basal cell carcinoma (BCC) differentiating into squamous cell carcinoma (SCC).
  • METHODS: The prospective, multicenter case series included all patients in Australia treated with MMS for BSC, who were monitored by the Skin and Cancer Foundation Australia between 1993 and 2002.
  • The tumors were diagnosed initially as BCC in 87.4% and as SCC in 12.0% of patients.
  • Of 98 patients who completed a 5-year follow-up period after MMS, 4 (4.1%) had disease recurrence.
  • CONCLUSIONS: The low 5-year disease recurrence rate of BSC with MMS emphasized the importance of margin-controlled excision using MMS.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods
  • [MeSH-minor] Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929123.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


98. Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R: Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol; 2006 Aug;142(2):293-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of periocular basal and squamous cell carcinoma: a series of 485 cases.
  • PURPOSE: To analyze the outcome of management of patients with basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) in a tertiary referral eye center in Sydney, Australia.
  • MAIN OUTCOME MEASURES: Survival period free of tumor, incomplete excision, recurrences, type of closure, and complications.
  • Morpheaform type of BCC (chi(2)P < .001), and medial canthus location BCCs (chi(2)P < .05) were associated with a higher incomplete resection rate.
  • Twenty-seven patients (5.6%) had a recurrent tumor.
  • CONCLUSIONS: In the setting of a tertiary referral center, incomplete primary resection of an eyelid skin cancer is the main risk factor for recurrence.
  • Incomplete resection is significantly associated with medial canthus location and morpheaform type of BCC and with moderately differentiated SCC.
  • MMS is the safer technique after incomplete tumor excision.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Eyelid Neoplasms / surgery. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876511.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Krahl D, Sellheyer K: Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol; 2007 Oct;34(10):782-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
  • It is diagnostically highly reliable in the differentiation between basal cell carcinoma and cutaneous squamous cell carcinoma.
  • In this study, we report its application in the differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and basal cell carcinoma.
  • METHODS: Biopsy samples from 28 sclerosing and infiltrating basal cell carcinomas, 13 microcystic adnexal carcinomas and 16 desmoplastic trichoepitheliomas were examined after immunohistochemical staining with Ber-EP4.
  • RESULTS: Ber-EP4 did not label any of the microcystic adnexal carcinomas, whereas all 28 basal cell carcinomas were Ber-EP4 positive.
  • Only one basal cell carcinoma was weakly positive.
  • Twelve of the 16 desmoplastic trichoepitheliomas were immunoreactive with Ber-EP4 and the staining was more variable than those of basal cell carcinomas.
  • CONCLUSIONS: Ber-EP4 reliably differentiates microcystic adnexal carcinoma from basal cell carcinoma to the same extent as it distinguishes the latter tumor from squamous cell carcinoma.
  • While it stains the majority of desmoplastic trichoepitheliomas, these tumors still have to be considered in the differential diagnosis with microcystic adnexal carcinoma, when Ber-EP4 is applied.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Sclerosis / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880584.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


100. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement